SBC Medical Group Holdings Incorporated (SBC) Key Metrics
SBC valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $530.7M
- Enterprise value
- $362.4M
- P/E (TTM)
- 11.0 10-yr median 11.5
- Forward P/E
- 9.3
- PEG ratio
- 1.87
- Price / sales
- 3.0 10-yr median 2.6
- Price / book
- 1.9 10-yr median 2.8
- EV / EBITDA
- 4.6 10-yr median 5.5
- Dividend yield
- —
- Beta
- 0.55
SBC key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSBC valuation Price multiples at each fiscal year-end price.
SBC returns How much profit the business earns on the capital it uses.
SBC per-share figures Results divided by the shares outstanding at year-end.
SBC financial health Debt, liquidity and how easily interest is covered.
SBC efficiency & capital use Working capital cycle and where the cash goes.
SBC valuation history
SBC returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SBC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SBC cash returned to shareholders
SBC price vs earnings per share
SBC key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $443.9M | $536.9M | $1.01B | — |
| Enterprise value | $331.5M | $424.0M | $934.3M | — |
| P/E ratio | 8.7 | 11.5 | 25.8 | — |
| Price / sales | 2.6 | 2.6 | 5.2 | — |
| Price / book | 1.8 | 2.8 | 7.1 | — |
| Price / free cash flow | 12.1 | 31.3 | 25.7 | — |
| Price / operating cash flow | 11.4 | 26.1 | 20.0 | — |
| EV / sales | 1.9 | 2.1 | 4.8 | — |
| EV / EBITDA | 3.9 | 5.5 | 10.9 | — |
| EV / free cash flow | 9.1 | 24.7 | 23.7 | — |
| Earnings yield | 11.5% | 8.7% | 3.9% | — |
| Free cash flow yield | 8.2% | 3.2% | 3.9% | — |
| Shareholder yield (dividends + buybacks) | 1.1% | 0.0% | — | — |
| Share price at fiscal year-end | $4.31 | $5.56 | $10.77 | $10.20 |
| Per share | ||||
| Revenue per share | $1.69 | $2.13 | $2.05 | — |
| Earnings per share | $0.50 | $0.48 | $0.42 | — |
| Operating cash flow per share | $0.38 | $0.21 | $0.54 | — |
| Free cash flow per share | $0.35 | $0.18 | $0.42 | — |
| Cash per share | $1.59 | $1.29 | $1.09 | — |
| Book value per share | $2.41 | $2.02 | $1.51 | — |
| Tangible book value per share | $1.80 | $1.96 | $1.26 | — |
| Capex per share | $0.02 | $0.04 | $0.12 | — |
| Debt per share | $0.50 | $0.13 | $0.24 | — |
| Shares outstanding | 103.0M | 96.6M | 94.2M | — |
| Change in shares outstanding | +6.7% | +2.5% | — | — |
| Returns & profitability | ||||
| Return on equity (ROE) | 23.0% | 27.6% | 31.8% | 6.0% |
| Return on invested capital (ROIC) | 38.5% | 61.9% | 57.1% | 14.9% |
| Return on assets (ROA) | 15.8% | 17.8% | 16.3% | 2.8% |
| Return on tangible assets | 16.1% | 17.9% | 16.7% | 2.9% |
| Free cash flow margin | 21.1% | 8.4% | 20.4% | −14.4% |
| Income quality (OCF / net income) | 0.76 | 0.44 | 1.29 | −0.01 |
| Financial health | ||||
| Total debt | $51.6M | $12.2M | $22.9M | $16.1M |
| Cash & short-term investments | $164.1M | $125.0M | $103.0M | $53.6M |
| Net debt | −$112.5M | −$112.8M | −$80.2M | −$37.5M |
| Debt / equity | 0.21 | 0.06 | 0.16 | 0.15 |
| Debt / assets | 0.14 | 0.05 | 0.09 | 0.07 |
| Net debt / EBITDA | −1.32 | −1.46 | −0.93 | −1.27 |
| Current ratio | 3.78 | 3.01 | 1.79 | 1.12 |
| Quick ratio | 3.74 | 2.99 | 1.76 | 1.10 |
| Interest coverage | 420.3 | — | — | 639.9 |
| Working capital | $170.1M | $123.3M | $73.5M | $11.7M |
| Invested capital | $135.8M | $82.3M | $62.0M | $67.7M |
| Tangible asset value | $200.1M | $188.8M | $120.5M | $96.7M |
| Net current asset value | $114.1M | $113.4M | $50.9M | −$4.7M |
| Graham number | $5.18 | $4.68 | $3.77 | — |
| Graham net-net per share | $0.86 | $0.94 | $0.31 | — |
| Capital allocation | ||||
| Share buybacks (net) | $5.0M | $0 | — | — |
| Dividends + buybacks / free cash flow | 13.7% | 0.0% | — | — |
| Capex / revenue | 1.4% | 1.7% | 5.8% | 14.3% |
| Capex / operating cash flow | 6.1% | 16.6% | 22.1% | — |
| Capex / depreciation | 0.88 | 0.90 | 0.92 | 4.21 |
| Stock-based compensation / revenue | 0.0% | 6.3% | 0.0% | — |
| SG&A / revenue | 33.9% | 34.1% | 34.2% | 53.7% |
| Efficiency | ||||
| Days sales outstanding | 106.5 | 90.0 | 91.3 | 91.5 |
| Days of inventory on hand | 16.9 | 17.0 | 14.4 | 8.3 |
| Days payables outstanding | 126.8 | 151.8 | 135.8 | 94.3 |
| Cash conversion cycle (days) | -3.4 | -44.8 | -30.2 | 5.5 |
| Receivables turnover | 3.43 | 4.05 | 4.00 | 3.99 |
| Payables turnover | 2.88 | 2.40 | 2.69 | 3.87 |
| Inventory turnover | 21.61 | 21.53 | 25.33 | 43.94 |
| Asset turnover | 0.54 | 0.78 | 0.80 | 0.77 |
| Average receivables | $50.6M | $50.7M | $48.4M | $43.6M |
| Average payables | $16.1M | $20.5M | $20.9M | $15.3M |
| Average inventory | $2.1M | $2.3M | $2.2M | $1.4M |
| Intangibles / total assets | 16.6% | 2.3% | 9.0% | 4.9% |
Computed from SBC's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SBC valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), SBC Medical traded at 8.7 times earnings, against a 4-year median of 11.5. Based on the latest twelve months, the trailing P/E is 11.0 and the forward P/E is 9.3. SBC Medical earned a return on equity of 23.0% and a return on invested capital of 38.5% in fiscal 2025. It ended the year with $51.6 million of debt and $164.1 million in cash and short-term investments, a net cash position of $112.5 million. It returned $5.0 million to shareholders: $0 in dividends and $5.0 million in share buybacks, 14% of free cash flow.
See the SBC income statement, the SBC chart for price history, or the SBC stock overview for the latest quote and news.
SBC key metrics FAQ
What is SBC Medical's P/E ratio?
SBC Medical's trailing P/E ratio is 11.0 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 9.3. At the end of fiscal 2025 it was 8.7, compared with a 4-year median of 11.5.
What is SBC Medical's EV/EBITDA?
SBC Medical's enterprise value was 3.9 times EBITDA at the end of fiscal 2025 (enterprise value $331.5 million, EBITDA $84.9 million); the current EV/EBITDA is 4.6.
What is SBC Medical's return on equity?
SBC Medical's return on equity (ROE) was 23.0% in fiscal 2025: net income of $51.0 million on average shareholders' equity of $221.7 million.
What is SBC Medical's ROIC?
SBC Medical's return on invested capital was 38.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does SBC Medical have?
SBC Medical had total debt of $51.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.21 and more cash than debt.
Does SBC Medical buy back its shares?
Yes. SBC Medical spent $5.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +6.7% over the year, to 103.0M..
What is SBC Medical's free cash flow yield?
SBC Medical generated $36.6 million of free cash flow in fiscal 2025, a free cash flow yield of 8.2% on its market value at year-end ($443.9 million).
What is SBC Medical's current ratio?
SBC Medical's current ratio was 3.78 at the end of fiscal 2025: current assets were 3.78 times current liabilities.